<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809273</url>
  </required_header>
  <id_info>
    <org_study_id>GrowfulPower-001</org_study_id>
    <nct_id>NCT03809273</nct_id>
  </id_info>
  <brief_title>Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI</brief_title>
  <acronym>HEARTRIP</acronym>
  <official_title>Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI: a Prospective，Muhicenter,Doubleblind, Double-dummy, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the effect of Yangxinshi on exercise tolerance of patients with
      percutaneous coronary intervention (PCI) for the first time with Trimetazidine.Half of
      participants will receive Yangxinshi and Trimetazidine mimic tablets in combination,While the
      other half will receive Trimetazidine and Yangxinshi mimic tablets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Primary Purpose of this study is to compare the effect of Yangxinshi on exercise
      tolerance of patients with percutaneous coronary intervention (PCI) for the first time with
      Trimetazidine, The target patients are the people who underwent PCI for the first time and
      can be carried on Cardiopulmonary exercise test. The treatment period was 24 weeks. The
      patients were randomly divided into two groups.： A: Yangxinshi pill 3 pills /tid and
      Trimetazidine mimic tablets 20mg/tid B: Trimetazidine mimic tablets 20mg/tid and Yangxinshi
      pill 3 pills /tid The patients were followed up for 0 weeks, 4 weeks, 12 weeks, 24 weeks and
      28 weeks after entering the group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in METs assessed by the CPET</measure>
    <time_frame>24 weeks</time_frame>
    <description>MET=Metabolic Equivalent of Task; CPET=Cardiopulmonary Exercise Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of anaerobic threshold (AT) by CPET</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major cardiovascular events (MACE)</measure>
    <time_frame>4,12,24 and 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHQ-9 Depression Scale</measure>
    <time_frame>24 weeks</time_frame>
    <description>PHQ=Patient health questionaire, score range: 0-27</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Seattle Angina Questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>The Seattle Angina Questionaire (SAQ) quantifies patients'physical limitations caused by angina. The scale is transformed to a score of 0 to 100, where higher scores indicate better function (less physical limitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of angina pectoris</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of METs&gt;7 patients</measure>
    <time_frame>24 weeks</time_frame>
    <description>MET=Metabolic Equivalent of Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of VO2max by CPET</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of VO2/HR by CPET</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of VO2/W by CPET</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAD-7 Anxiety Screening Scale</measure>
    <time_frame>24 weeks</time_frame>
    <description>GAD=Generalized Anxiety Disorder, score range: 0~21</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">668</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Yangxinshi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trimetazidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yangxinshi</intervention_name>
    <description>Yangxinshi pill 3 pills /tid</description>
    <arm_group_label>Yangxinshi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine</intervention_name>
    <description>Trimetazidine 20mg/tid</description>
    <arm_group_label>Trimetazidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yangxinshi mimic</intervention_name>
    <description>Yangxinshi mimic tablets 3 pills /tid</description>
    <arm_group_label>Trimetazidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine mimic</intervention_name>
    <description>Trimetazidine mimic tablets 20mg/tid</description>
    <arm_group_label>Yangxinshi</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18~ 75, gender is not limited；

          -  The patient within two month after PCI operation for the first time；

          -  The patient had 1-2 coronary artery lesions with complete revascularization：At least
             one drug eluting stent was implanted，and residual coronary artery stenosis after PCI
             &lt;30%；

          -  Have not revascularization plan within 6 months；

          -  After being evaluated by clinicians on aerobic exercise ability，patients can carry out
             early rehabilitation in hospital and exercise cardiopulmonary rehabilitation outside
             the hospital；

          -  Coronary heart disease patients with Qi Deficiency and Blood Stasis Syndrome；

          -  Participants voluntarily participated in and signed informed consent；

        Exclusion Criteria:

          -  Patients was diagnosed with AMI as the first diagnosis in the past month, and then
             hospitalized for PCI operation；

          -  Patients with absolute and relative contraindications in cardiopulmonary exercise
             test；

          -  Any drug allergy to Yangxinshi pill and trimetazidine；

          -  Patients have taken regular Yangxinshi pill, trimetazidine or other Chinese patent
             medicine regularly in the past month；

          -  Patients are intolerant of aspirin, clopidogrel, statins, beta blockers or ACEI drugs
             (such as massive hemorrhage, severe hypotension, etc.)；

          -  History of stroke (cerebral hemorrhage, subarachnoid hemorrhage, cerebral thrombosis,
             cerebral embolism and stroke of unknown type) or lower extremity arterial disease in
             the past 6 months

          -  Active bleeding disease within 6 months；

          -  Combined with severe liver and kidney dysfunction (creatinine clearance ≤ 30ml / min
             or in the active stage of kidney disease, serum aminotransferase ≥ 3 × upper limit of
             clinical reference), other lifethreatening serious primary or psychiatric diseases and
             malignant tumors

          -  Hemoglobin &lt;90 g/L；

          -  Cardiac function (NYHA) grade IV or echocardiography LVEF &lt; 30%；

          -  Venous blood pressure &lt;100/60 mmHg；

          -  In past 6 months, have medical history of: pregnancy, prepare or suspected of
             pregnancy, abortion, breastfeeding or after childbirth

          -  The expected survival period is less than one year.；

          -  Patients who are participating in other clinical studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Zhang, MD</last_name>
      <phone>0086-13352459427</phone>
      <email>zj2fish@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Han Yaling</investigator_full_name>
    <investigator_title>Director, clinical professor</investigator_title>
  </responsible_party>
  <keyword>Cardiopulmonary Exercise Test</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimetazidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

